Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267135 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Phase 3 study of Chronic Scalp Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
- 17
- Study locations
NCT02267135 is a Phase 3 study of Chronic Scalp Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 102 participants. The trial reports 17 study locations across 13 states.
The verdict
NCT02267135, a Phase 3 study of Chronic Scalp Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Secukinumab 300 mg
Study Locations (17)
Massachusetts
- Novartis Investigative Site - Andover
- Novartis Investigative Site - Boston
New York
- Novartis Investigative Site - New York
- Novartis Investigative Site - New York
Pennsylvania
- Novartis Investigative Site - Hershey
- Novartis Investigative Site - Pittsburgh
Utah
- Novartis Investigative Site - Salt Lake City
- Novartis Investigative Site - West Jordan
California
- Novartis Investigative Site - Sacramento
Colorado
- Novartis Investigative Site - Aurora
Connecticut
- Novartis Investigative Site - Trumbull
Maryland
- Novartis Investigative Site - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2014-09-29 |
| Est. Completion | 2015-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02267135
The ClinicalTrials.gov registry entry for NCT02267135 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Scalp Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02267135 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02267135 about?
NCT02267135 is a clinical study titled "Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis". This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
What is the current status of trial NCT02267135?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2014-09-29. Estimated completion is 2015-12-07.
What conditions does trial NCT02267135 study?
This clinical trial studies the following conditions: Chronic Scalp Psoriasis.
What interventions are being tested in trial NCT02267135?
The interventions under investigation include: Placebo (BIOLOGICAL), Secukinumab 300 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02267135?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02267135 being conducted?
This trial has 17 study locations across California, Colorado, Connecticut, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.